85333-26-2

Usage

Uses

Used in Organic Synthesis:
2-Amino-4-(benzyloxy)pyridine is used as a building block in organic synthesis for the creation of various biologically active molecules, contributing to the development of new pharmaceuticals and chemical compounds.
Used in Pharmaceutical Research:
In pharmaceutical research, 2-Amino-4-(benzyloxy)pyridine is utilized as a key intermediate for the synthesis of pharmaceuticals and fine chemicals, playing a crucial role in advancing drug discovery and innovation.
Used in Cancer Treatment Research:
2-Amino-4-(benzyloxy)pyridine is studied for its potential therapeutic applications in the treatment of cancer, exploring its ability to target and combat cancer cells, offering a promising avenue for cancer therapy development.
Used in the Production of Pharmaceuticals and Fine Chemicals:
As an important intermediate, 2-Amino-4-(benzyloxy)pyridine is employed in the manufacturing process of various pharmaceuticals and fine chemicals, ensuring the production of high-quality and effective products for diverse applications.

InChI:InChI=1/C12H12N2O/c13-12-8-11(6-7-14-12)15-9-10-4-2-1-3-5-10/h1-8H,9H2,(H2,13,14)

Upstream product

• 1124-33-0 4-nitraminopyridine N-oxide 
• 23056-36-2 2-chloro-4-nitropyridine 
• 34941-91-8 2-chloro-4-fluoropyridine 
• 26452-80-2 2,4-dichloropyridine 
• 53937-02-3 4-(benzyloxy)pyridin-2(1H)-one 
• 1184918-18-0 t-butyl(4-benzyloxypyridin-2-yl)amine 
• 2683-66-1 4-benzyloxypyridine-N-oxide 
• 100-51-6 benzyl alcohol 
• 182556-72-5 2-chloro-4-(benzyloxy)pyridine 

Downstream Products

• 1415834-64-8 N-(4-benzyloxypyridin-2-yl)-2-(2,6-difluorophenyl)acetamide 
• 1415834-60-4 N-(4-benzyloxypyridin-2-yl)-3-phenylpropionamide 
• 1415834-59-1 N-(4-benzyloxypyridin-2-yl)-2-phenylacetamide 
• 1415834-62-6 N-(4-benzyloxypyridin-2-yl)-2-(4-fluorophenyl)acetamide 

Relevant academic research and scientific papers

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

BENZIMIDAZOLE DERIVATIVES AND AZA-BENZIMIDAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS

The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2)

Novel 4-substituted 2-pyridin-2-ylamides were developed using in-silico ligand-based drug design (LBDD) in an attempt to identify inhibitors of SH2-containing 5′-inositol phosphatase 2 (SHIP2), which is implicated in insulin-resistant type 2 diabetes. Among the compounds synthesized, N-[4-(4-chlorobenzyloxy)pyridin-2-yl]-2-(2,6-difluorophenyl)- acetamide (CPDA, 4a) was identified as a potent SHIP2 inhibitor. CPDA was found to enhance in vitro insulin signaling through the Akt pathway more efficiently than the previously reported SHIP2 inhibitor AS1949490, and ameliorated abnormal glucose metabolism in diabetic (db/db) mice.

Processes and intermediates for the preparation of N4-phenyl-quinazoline-4-amine derivatives

This invention provides compounds of Formula (I), wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

GLUCOKINASE ACTIVATORS

Provided are compounds of formula I that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase. (Formula I) wherein R2, L, Z, Y, G and R1 are as defined in the claims.